COMBINATION OF VEGFR2 AND IGF1R INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES

• US 20110123545A1
• Filed: 11/24/2010
• Published: 05/26/2011
• Est. Priority Date: 11/24/2009
• Status: Abandoned Application

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Carvajal, Irvith M., Carboni, Joan M., Gottardis, Marco M., Attar, Ricardo M., Marsh, H. Nicholas, Barnhart, Bryan C.
• Application Number:
  US12/953,541
• Publication Number:
  US 20110123545A1
• Time in Patent Office: Days
• US Class Current: 424/158.1
• CPC Class Codes: A61K 2039/507 Comprising a combination of two or more separate antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/78 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• CPC Class Codes: C07K 16/2863 against receptors for growth factors, growth regulators
• CPC Class Codes: C07K 2318/20 Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Abstract

Methods for increasing endothelial cell apoptosis under hypoxic conditions in a patient undergoing a treatment that comprises an IGF1R inhibitor, the method comprising administering to the patient a VEGFR2 inhibitor

Claims

1. A method for increasing endothelial cell apoptosis under hypoxic conditions in a patient undergoing a treatment that comprises an IGF1R inhibitor, said method comprising administering to said patient a VEGFR2 inhibitor.

2. The method of claim 1 wherein said IGF1R inhibitor and said VEGFR2 inhibitor are co-administered to said patient.

3. The method of claim 1 wherein at least one of said IGF1R inhibitor and said VEGFR2 inhibitor is not derived from 10Fn3.

4. A method for identifying a molecule for the treatment of a proliferative disease comprising the steps of:

(i) identifying an IGF1R inhibitor;

(ii) identifying a VEGFR2 inhibitor; and

(iii) combining the properties of said first agent and send second agent in a molecule that is effective for the treatment of said proliferative disease.